Vanguard Group’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-6,020,594
| Closed | -$311M | – | 4611 |
|
|
2022
Q3 | $311M | Buy |
6,020,594
+214,367
| +4% | +$8.86M | 0.01% | 1111 |
|
|
2022
Q2 | $144M | Buy |
5,806,227
+686,912
| +13% | +$15.1M | ﹤0.01% | 1618 |
|
|
2022
Q1 | $128M | Buy |
5,119,315
+20,335
| +0.4% | +$571K | ﹤0.01% | 1804 |
|
|
2021
Q4 | $186M | Buy |
5,098,980
+255,927
| +5% | +$8.98M | ﹤0.01% | 1657 |
|
|
2021
Q3 | $82.8M | Sell |
4,843,053
-16,651
| -0.3% | -$259K | ﹤0.01% | 2084 |
|
|
2021
Q2 | $65.1M | Sell |
4,859,704
-9,362
| -0.2% | -$231K | ﹤0.01% | 2231 |
|
|
2021
Q1 | $249M | Buy |
4,869,066
+121,596
| +3% | +$7.32M | 0.01% | 1453 |
|
|
2020
Q4 | $294M | Buy |
4,747,470
+167,003
| +4% | +$9.56M | 0.01% | 1214 |
|
|
2020
Q3 | $251M | Buy |
4,580,467
+957,207
| +26% | +$51.5M | 0.01% | 1127 |
|
|
2020
Q2 | $208M | Buy |
3,623,260
+1,393,472
| +62% | +$75.8M | 0.01% | 1249 |
|
|
2020
Q1 | $89.6M | Buy |
2,229,788
+148,106
| +7% | +$6.29M | ﹤0.01% | 1586 |
|
|
2019
Q4 | $82.3M | Buy |
2,081,682
+186,411
| +10% | +$3.27M | ﹤0.01% | 1876 |
|
|
2019
Q3 | $12.8M | Buy |
1,895,271
+120,782
| +7% | +$907K | ﹤0.01% | 2699 |
|
|
2019
Q2 | $16.5M | Buy |
1,774,489
+488,063
| +38% | +$5.65M | ﹤0.01% | 2609 |
|
|
2019
Q1 | $17.9M | Sell |
1,286,426
-74,058
| -5% | -$847K | ﹤0.01% | 2557 |
|
|
2018
Q4 | $14.8M | Buy |
1,360,484
+30,990
| +2% | +$327K | ﹤0.01% | 2585 |
|
|
2018
Q3 | $16.8M | Buy |
1,329,494
+90,899
| +7% | +$1.1M | ﹤0.01% | 2664 |
|
|
2018
Q2 | $16.3M | Buy |
1,238,595
+16,313
| +1% | +$195K | ﹤0.01% | 2659 |
|
|
2018
Q1 | $16.6M | Sell |
1,222,282
-14,490
| -1% | -$149K | ﹤0.01% | 2574 |
|
|
2017
Q4 | $7.36M | Buy |
1,236,772
+4,782
| +0.4% | +$32.8K | ﹤0.01% | 2973 |
|
|
2017
Q3 | $9.14M | Buy |
1,231,990
+19,916
| +2% | +$166K | ﹤0.01% | 2851 |
|
|
2017
Q2 | $11.3M | Buy |
1,212,074
+13,344
| +1% | +$98K | ﹤0.01% | 2714 |
|
|
2017
Q1 | $8.73M | Buy |
1,198,730
+47,475
| +4% | +$342K | ﹤0.01% | 2820 |
|
|
2016
Q4 | $8.52M | Buy |
1,151,255
+32,483
| +3% | +$234K | ﹤0.01% | 2819 |
|
|
2016
Q3 | $6.76M | Buy |
1,118,772
+35,697
| +3% | +$169K | ﹤0.01% | 2858 |
|
|
2016
Q2 | $4.86M | Buy |
1,083,075
+65,013
| +6% | +$244K | ﹤0.01% | 2997 |
|
|
2016
Q1 | $2.54M | Buy |
1,018,062
+63,009
| +7% | +$229K | ﹤0.01% | 3290 |
|
|
2015
Q4 | $7.74M | Buy |
955,053
+11,670
| +1% | +$82.6K | ﹤0.01% | 2775 |
|
|
2015
Q3 | $5.71M | Buy |
943,383
+78,190
| +9% | +$565K | ﹤0.01% | 2905 |
|
|
2015
Q2 | $7.12M | Buy |
865,193
+16,442
| +2% | +$131K | ﹤0.01% | 2845 |
|
|
2015
Q1 | $6.41M | Buy |
848,751
+21,121
| +3% | +$165K | ﹤0.01% | 2865 |
|
|
2014
Q4 | $5.65M | Buy |
827,630
+51,605
| +7% | +$273K | ﹤0.01% | 2833 |
|
|
2014
Q3 | $3.49M | Buy |
776,025
+28,189
| +4% | +$149K | ﹤0.01% | 3022 |
|
|
2014
Q2 | $4.38M | Buy |
747,836
+11,402
| +2% | +$64K | ﹤0.01% | 2906 |
|
|
2014
Q1 | $4.88M | Buy |
736,434
+106,948
| +17% | +$743K | ﹤0.01% | 2841 |
|
|
2013
Q4 | $3.65M | Buy |
629,486
+153,033
| +32% | +$789K | ﹤0.01% | 2950 |
|
|
2013
Q3 | $2.65M | Buy |
476,453
+6,643
| +1% | +$71.8K | ﹤0.01% | 3027 |
|
|
2013
Q2 | $6.64M | Buy |
+469,810
| New | +$6.09M | ﹤0.01% | 2515 |
|
Other funds holding CCXI
Vanguard Group's CCXI Position: Q4 2022 in Review
Vanguard Group sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 6,020,594 shares — an estimated $311M sold.
Vanguard Group first reported a position in CCXI in Q2 2013 and held it in 38 quarters. The position peaked at $311M in Q3 2022. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.
- Vanguard Group reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
- Vanguard Group sold 6,020,594 ChemoCentryx, Inc. shares in Q4 2022, an estimated $311M.
- Vanguard Group first reported a position in ChemoCentryx, Inc. in Q2 2013 and held it in 38 quarters.
- Vanguard Group's ChemoCentryx, Inc. position peaked at $311M in Q3 2022.
- 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.
Based on Vanguard Group's 13F filing for Q4 2022, filed 10 Feb 2023.